NuCana (NCNA) Shares Outstanding (2015 - 2025)
NuCana (NCNA) reported Shares Outstanding (Entity) of $210.3 billion for Q2 2022, down 9.84% on a YoY basis from $233.3 billion in Q2 2021, and down 6.13% sequentially from $224.1 billion in Q1 2022.
NuCana (NCNA) Shares Outstanding (2015 - 2025) Analysis & Trends
NuCana (NCNA) has 8 years of Shares Outstanding (Entity) data on file, last reported at $210.3 billion in Q2 2022.
- For the quarter ending Q2 2022, Shares Outstanding (Entity) fell 9.84% year-over-year to $210.3 billion; the trailing twelve-month figure through Jun 2022 stood at $210.3 billion (down 9.84% YoY), and the FY2021 full-year result was $229.1 billion, up 47.19% from the prior year.
- Shares Outstanding (Entity) slipped to $210.3 billion in Q2 2022, from $224.1 billion in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $233.3 billion in Q2 2021 to a low of $127.8 billion in Q3 2019.
- A 5-year average of $166.2 billion and a median of $140.1 billion in 2018 frame the typical range for Shares Outstanding (Entity).
- Across the five-year window, Shares Outstanding (Entity) surged 79.74% in 2021 and decreased 9.84% in 2022, its largest moves.
- Tracing NCNA's Shares Outstanding (Entity) over 5 years: stood at $131.6 billion in 2018, then gained by 1.03% to $133.0 billion in 2019, then increased by 20.35% to $160.1 billion in 2020, then soared by 40.24% to $224.5 billion in 2021, then fell by 6.3% to $210.3 billion in 2022.
- Business Quant data shows NCNA's Shares Outstanding (Entity) at $210.3 billion in Q2 2022, $224.1 billion in Q1 2022, and $224.5 billion in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6,012.74 Bn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 47.82 Bn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 118.76 Bn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.44 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 254.10 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 400.00 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 62.06 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 198.10 Mn |
| 10 | NuCana | 14.60 Bn | 14.60 Bn | - | 11.23 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.23 Bn |
| Sep 30, 2025 | 18.48 Bn |
| Jun 30, 2025 | 5.17 Bn |
| Mar 31, 2025 | 30.36 Bn |
| Dec 31, 2024 | 14.84 Bn |
| Sep 30, 2024 | 12.08 Bn |
| Jun 30, 2024 | 11.33 Bn |
| Mar 31, 2024 | 10.72 Bn |
| Dec 31, 2023 | 420.58 Mn |
| Sep 30, 2023 | 10.53 Bn |
| Jun 30, 2023 | 10.48 Bn |
| Mar 31, 2023 | 419.03 Mn |
| Dec 31, 2022 | 417.88 Mn |
| Sep 30, 2022 | 417.57 Mn |
| Jun 30, 2022 | 417.57 Mn |
| Mar 31, 2022 | 417.46 Mn |
| Dec 31, 2021 | 416.33 Mn |
| Sep 30, 2021 | 417.32 Mn |
| Jun 30, 2021 | 417.30 Mn |
| Mar 31, 2021 | 413.19 Mn |